Table 2 The top 5 most resistant tumoroid compositions for each treatment are listed with their corresponding normalized viability values
Most resistant tumoroid cellular composition for each treatment | ||||||
|---|---|---|---|---|---|---|
Order of resistance | Overall drug response | Carboplatin drug response | Paclitaxel drug response | PACMA31 drug response | N773 drug response | SC144 drug response |
5 most resistant | Composition 11 60 OVCAR3 + 500 U937 | Composition 11 60 OVCAR3 + 500 U937 | Composition 14 60 OVCAR3 + 400 MSC + 400 EC + 100 U937 | Composition 11 60 OVCAR3 + 500 U937 | Composition 14 60 OVCAR3 + 400 MSC + 400 EC + 100 U937 | Composition 15 60 OVCAR3 + 200 MSC + 200 EC + 500 U937 |
4 | Composition 15 60 OVCAR3 + 200 MSC + 200 EC + 500 U937 | Composition 21 60 OVCAR3 + 500 EC + 500 U937 | Composition 5 60 OVCAR3 + 60 MSC + 60 EC + 60 U937 | Composition 7 300 OVCAR3 + 60 MSC + 60 EC + 60 U937 | Composition 11 60 OVCAR3 + 500 U937 | Composition 1 30 OVCAR3 |
3 | Composition 5 60 OVCAR3 + 60 MSC + 60 EC + 60 U937 | Composition 22 60 OVCAR3 + 500 MSC + 500 U937 | Composition 10 60 OVCAR3 + 500 EC | Composition 4 120 OVCAR3 + 20 MSC + 20 EC + 20 U937 | Composition 16 60 OVCAR3 + 200 MSC + 500 EC + 200 U937 | Composition 2 60 OVCAR3 |
2 | Composition 22 60 OVCAR3 + 500 MSC + 500 U937 | Composition 5 60 OVCAR3 + 60 MSC + 60 EC + 60 U937 | Composition 16 60 OVCAR3 + 200 MSC + 500 EC + 200 U937 | Composition 5 60 OVCAR3 + 60 MSC + 60 EC + 60 U937 | Composition 15 60 OVCAR3 + 200 MSC + 200 EC + 500 U937 | Composition 12 60 OVCAR3 + 400 MSC + 200 EC + 100 U937 |
1 least resistant | Composition 23 60 OVCAR3 + 500 MSC + 500 EC + 500 U937 | Composition 13 300 MSC + 300 EC + 300 U937 | Composition 15 60 OVCAR3 + 200 MSC + 200 EC + 500 U937 | Composition 15 60 OVCAR3 + 200 MSC + 200 EC + 500 U937 | Composition 22 60 OVCAR3 + 500 MSC + 500 U937 | Composition 7 300 OVCAR3 + 60 MSC + 60 EC + 60 U937 |
